Magenta Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Dianthus Therapeutics

16/05/2022 14:41

* Magenta Therapeutics Inc  MGTA.OQ  reported a quarterly
adjusted
loss of 39 cents​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of 31 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Magenta Therapeutics Inc's reported EPS for the quarter
was a
loss of 39 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Magenta Therapeutics Inc shares had fallen by 60.7% this
quarter and lost 74.3% so far this year.
    * The company reported a quarterly loss of $22.95 million.
    * Wall Street's median 12-month price target for Magenta
Therapeutics Inc is $6.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 01:41 p.m.  ​All
figures in US dollars unless otherwise stated